Puramed Bioscience Inc. Gross Margin
- Gross margin · 12 months: Value -11511.39%; Formula and calculation Gross profit / revenue. Period ending 2014-09-30..
Gross margin
Overview →Financial period ending 2014-09-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | -11511.39% | Gross profit / revenue. Period ending 2014-09-30. $-418.55K ÷ $3.64K × 100 ≈ -11511.39% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | -418.55K USD | Gross Profit |
| Revenue | 3.64K USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2014-09-30 | $-418.55K | $3.64K | (m) | -11511.39% |
| 2014-06-30 | $-443.86K | $0.00 | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) |
| 2013-09-30 | $-93.62K | $15.27K | (m) | -612.98% |
| 2013-06-30 | $-52.53K | $42.81K | (m) | -122.71% |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | $16.16K | $106.66K | (m) | 15.15% |
| 2012-09-30 | $521.77K | $715.34K | (m) | 72.94% |
| 2012-06-30 | $509.31K | $693.06K | (m) | 73.49% |
| 2012-03-31 | $585.46K | $760.02K | (m) | 77.03% |
| 2011-12-31 | $491.85K | $617.05K | (m) | 79.71% |
| 2011-09-30 | $2.39K | $10.25K | (m) | 23.32% |
| 2011-06-30 | $1.20K | $8.59K | (m) | 13.94% |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.